Amsterdam, the Netherlands – 22 February 2019 — Esperite N.V. (Euronext: ESP) and Polski Bank Komórek Macierzystych S.A. (WSE: PBKM) are pleased to announce that they have entered into an Memorandum of Understanding (MoU) regarding the potential acquisition by PBKM of substantially all Cryo-Save’s business related to stem cell banking (the Proposed Acquisition). The Proposed Acquisition leverages the respective strengths and quality standards of the two publicly traded companies that are both leading in the stem cell banking sector. Cryo-Save is one of the largest and longest operating stem cell bank in Europe, in which store more than 330.000 umbilical cord blood samples and tissues. [Read more…]
New York, NY; February 19, 2019 — Americord Registry announced today that it will begin offering five-compartment freezing bags for all new customers storing cord blood as well as the highest quality guarantee in the industry. While industry-standard freezing bags typically contain two compartments, one holding eighty percent of the cord blood and a second holding twenty percent, Americord’s new freezing bags contain five compartments with twenty percent of the cord blood in each compartment. [Read more…]
Signature Matrix and Signature Cord are the culmination of decades of research and clinical use of perinatal tissue by applied stem cell research expert and Amazon best-selling author, Neil Riordan, PA, PhD, and his experienced research and development team.
Signature Cord is a flowable umbilical cord tissue allograft that originates from the same tissue used to manufacture the purified, expanded mesenchymal stem cell product used by Stem Cell Institute in Panama to treat a variety of chronic conditions. This product is a natural source of growth factors and hyaluronic acid, and is naturally immune evasive. Most importantly, our proprietary Signature Process of manufacturing does not alter the innate regenerative properties of the umbilical cord tissue and maintains the source material integrity required for tissue repair. [Read more…]
StemCyte Receives Phase II Investigational New Drug (IND) Clearance from the U.S. Food and Drug Administration (FDA)
BALDWIN PARK, Calif., Jan. 3, 2019 — StemCyte is pleased to announce that the U.S. Food and Drug Administration (FDA), on December 14, 2018, approved its Phase II Investigational New Drug (IND) application for Allogeneic Human Leukocyte Antigen (HLA)-Matched Umbilical Cord Blood Mononuclear Stem Cells (UCBMNC) (MC001) for the treatment of spinal cord injury. [Read more…]
December 21, 2018, New York, NY — Americord Registry, LLC, a leading cord blood, cord tissue, and placental tissue bank, announced today the launch of its new website. The layout and functionality have been optimized for an improved user-experience that better serves Americord’s customers and individuals seeking more education about stem cell banking services. [Read more…]